Confirmatory Diagnosis of Advanced Gallbladder Cancer

Diagnostic Algorithm for Advanced Disease

The European Society for Medical Oncology recommends confirmatory diagnosis of advanced gallbladder cancer via pathological confirmation using core needle biopsy combined with comprehensive cross-sectional imaging (contrast-enhanced CT and MRI/MRCP) to establish both tissue diagnosis and disease extent 1, 2
Contrast-enhanced MRI with MRCP is the optimal initial imaging modality, providing superior delineation of the primary tumor, biliary anatomy, hepatic involvement, and vascular invasion, as suggested by the European Society for Medical Oncology and the British Society of Gastroenterology 3, 1
Contrast-enhanced CT of chest, abdomen, and pelvis is mandatory to detect lymphadenopathy, liver metastases, and distant metastases, according to the European Society for Medical Oncology and the British Society of Gastroenterology 3, 1, 4

Core needle biopsy is required for definitive diagnosis before initiating any nonsurgical treatment, as recommended by the European Association for the Study of the Liver and the European Society for Medical Oncology 5, 1
EUS-guided fine needle biopsy (FNB) is preferred when technically feasible, offering sensitivity of 84% and specificity of 100% for biliary malignancies, as reported by the American Society for Gastrointestinal Endoscopy 6
ERCP-guided brush cytology has limited sensitivity (40-70%) and should not be relied upon alone, according to the American Society for Gastrointestinal Endoscopy and the European Society for Medical Oncology 7, 6

Thoracic CT should be performed if not already done, to exclude pulmonary metastases, as recommended by the European Society for Medical Oncology and the British Society of Gastroenterology 1, 4
EUS with FNA/FNB should be used to evaluate and sample suspicious regional lymph nodes, as suggested by the European Society for Medical Oncology 1
Laparoscopy may be considered to detect occult peritoneal metastases, particularly if borderline resectable, according to the European Society for Medical Oncology and the British Society of Gastroenterology 8, 4

Molecular analysis is now recommended for all advanced gallbladder cancer considered suitable for systemic treatment, as stated by the European Society for Medical Oncology 1
Testing for actionable mutations including KRAS/MAPK, EGFR, FGFR2, IDH1/2, and MET signaling pathways should be performed, as recommended by the European Association for the Study of the Liver 5
Assessing microsatellite instability (MSI) status via IHC for mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) should be done, according to the European Society for Medical Oncology 1

CA 19-9 should be measured after biliary obstruction is relieved, as it is elevated in up to 85% of gallbladder cancer cases, as reported by the British Society of Gastroenterology 3
Markedly elevated CA 19-9 correlates with poor prognosis and can assess treatment response, according to the European Society for Medical Oncology 1

All suspected advanced gallbladder cancer cases must be reviewed by a multidisciplinary team including experienced radiologists, surgeons, medical oncologists, and pathologists to confirm diagnosis and staging, determine resectability versus unresectability, and plan treatment approach, as recommended by the European Society for Medical Oncology and the American Society for Gastrointestinal Endoscopy 7, 6